Asia Pacific Wearable Injectors Market Size, Share, and Analysis by 2027

The Asia Pacific Wearable Injectors market is expected to reach US$ 2939.97 million by 2027 from US$ 1160.40 million in 2019. The market is estimated to grow at CAGR of 12.4% from 2020 to 2027.

Wearable injectors are rapidly gaining their prominence in the Asia Pacific Wearable Injectors market owing to their capabilities in delivering high volume of viscous formulations. The administration of pharmaceuticals via intravenous (IV) infusion is expensive in healthcare settings. Self-administration of subcutaneous injections is expected to save 30–70% of costs. Moreover, administration through conventional methods poses risks such as inaccurate dosage and needle stick injuries. The rise in the number of biologic drugs that are not suitable for oral administration has increased the adoption of wearable injection devices. Higher dosage volumes and viscous formulations of these drugs are further emphasizing the need for alternative injection methods such as wearable injectors. For instance, the enFuse wearable injector manufactured by Enable Injections is used for subcutaneous delivery of high-volume therapeutics outside a healthcare facility. The company has also introduced mobile monitoring and larger volume capabilities to its high-volume wearable injectors.

A new category of wearable products has emerged, bridging the gap between functionality and cost while improving patient safety and quality of life. One such example is Stevanato Group’s cartridge-based wearable device, currently under development, received Best Innovation in Drug Delivery Device award at Pharma pack Awards in 2019. The product includes a disposable, wearable pod, and reusable handheld controller that serves as the user interface and control unit for the pod. This is used for varied therapeutic areas, including diabetes, hormone therapies, pain management, and Alzheimer’s disease treatment. Moreover, continuous development by leading players in upgrading the existing wearable injector portfolio is further driving the demand for wearable injectors. For instance, in February 2020, BD, a leading global medical technology company, completed a human clinical trial of the BD Libertas Wearable Injector. The award-winning injector is currently in development and is designed as a subcutaneous drug delivery system to deliver biologics with viscosities up to 50 cP in 2–5 mL and 5–10 mL configurations.

Asia Pacific Wearable Injectors – Market Segmentation

By Type

• On-body Injectors
• Off-body Injectors

By Application

• Diabetes
• Oncology
• Cardiovascular Disease
• Autoimmune Disease
• Other Applications

By End User

• Hospitals and Clinics
• Homecare Setting
• Other End User

By Country

• China
• Japan
• India
• South Korea
• Australia
• RoAPAC

Company Profiles

• BD
• CeQur SA
• Debiotech S.A
• E3D Elcam Drug Delivery Devices
• Gerresheimer AG
• Tandem Diabetes Care Inc
• West Pharmaceutical Services, Inc
• Ypsomed AG
• Medtronic
• Amgen, Inc.

Asia Pacific Wearable Injectors Report Scope